Venture Capitalists Step Up Investment in Services
As products from technology-driven start-ups increasingly fail to gain support from customers and investors, VCs are steering more of their life sciences funds towards services. The withdrawal from technology , however, is more like a fire drill than a stampede, owing to the non-proprietary nature of medical service businesses. Yet the inefficiencies in US health care beg for solutions and VCs plan to oblige--largely by proferring information systems.
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.